对14例鼻腔和鼻窦黏膜黑色素瘤患者的单中心回顾性系列研究。
Single-center retrospective series of fourteen patients with mucosal melanoma of the nasal cavity and paranasal sinuses.
作者信息
Letievant J-C, Poupart M, Ambrun A, Colin C, Pignat J-C
机构信息
CHU Croix-Rousse, Service d'ORL et de Chirurgie de la Face et du Cou, 69006 Lyon, France.
CHU Croix-Rousse, Service d'ORL et de Chirurgie de la Face et du Cou, 69006 Lyon, France.
出版信息
Eur Ann Otorhinolaryngol Head Neck Dis. 2016 Dec;133(6):387-391. doi: 10.1016/j.anorl.2016.07.003. Epub 2016 Aug 5.
OBJECTIVES
Mucosal melanoma of the nasal cavity and paranasal sinuses is a rare and highly aggressive tumor. We report our experience over 20 years in management of this tumor.
PATIENTS AND METHODS
A retrospective study included 14 patients with primary sinonasal mucosal melanoma.
RESULTS
The series comprised 8 male and 6 female patients, with a median age at diagnosis of 67 years. Staging on the American Joint Committee on Cancer classification of sinus cancer was 14% T2, 22% T3, 75% T4a and 7% T4b. All patients underwent primary surgical treatment; 71% received adjuvant external radiotherapy. Median recurrence-free interval was 28.7 months. Two- and 5-year overall survival was 43% and 32%, respectively. Median follow-up was 43 months.
CONCLUSIONS
Mucosal melanomas of the nasal cavity and paranasal sinuses are very specific entities. Limited pathophysiological knowledge still precludes effective medium- and long-term management. Future treatment will probably be based on global adjuvant or neoadjuvant-targeted chemotherapy.
目的
鼻腔和鼻窦黏膜黑色素瘤是一种罕见且侵袭性很强的肿瘤。我们报告20多年来对该肿瘤的治疗经验。
患者与方法
一项回顾性研究纳入了14例原发性鼻窦黏膜黑色素瘤患者。
结果
该系列包括8例男性和6例女性患者，诊断时的中位年龄为67岁。根据美国癌症联合委员会鼻窦癌分类分期，14%为T2期，22%为T3期，75%为T4a期，7%为T4b期。所有患者均接受了初次手术治疗；71%接受了辅助外照射放疗。无复发生存期的中位数为28.7个月。2年和5年总生存率分别为43%和32%。中位随访时间为43个月。
结论
鼻腔和鼻窦黏膜黑色素瘤是非常特殊的疾病。有限的病理生理知识仍然妨碍有效的中长期治疗。未来的治疗可能会基于全身性辅助或新辅助靶向化疗。
Zotero 插件